This content was accurate at the time of release, 1 November 2021. Accreditation for this course expired on 2 November 2022. If you would still like an activity completion certificate, send your request to [email protected].
This online learning module is designed to raise awareness for HCM and provide you with an understanding of the risk factors for sudden cardiac death in HCM patients. It assists clinicians in community practice or those with an interest in HCM management to:
- recognise major risk factors for sudden cardiac death in adult and pediatric HCM patients
- implement strategies for sudden death prevention
- know when referral to an HCM expert center is appropriate
This online learning module is designed to be completed in 60 minutes.
Target audience: Family/general physicians, general/community cardiologists, cardiac nurses, paediatricians, paediatric nurses, genetic counselors
Funding disclosure: This activity is supported by educational grant funding from Bristol Myers Squibb, Cytokinetics and Sanofi.
Learners may participate in this educational activity free of charge.
- Sudden cardiac death and major risk factors in adult HCM patients
- Major risk factors in pediatric HCM patients
- Reducing SCD risk
- ICD recommendations
By the end of this activity, learners will be able to:
- Explain recommended risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) patients and apply reasoning to a patient
- Recall major risk factors for SCD in adult HCM patients and interpret these for an example patient case
- Outline risk factors for SCD in pediatric HCM patients and analyze these in a sample patient
- List the types of implantable cardioverter-defibrillator (ICD) available for SCD prevention
- Recall the indications for which different types of ICDs are appropriate
Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.
Dr John Lynn Jefferies, MD, Professor and Chief of Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Methodist University Hospital/ University of Tennessee, St Jude Children’s Research Hospital, has received financial compensation for consulting for Abbott, Novartis, and Pfizer, and received research grants from Myokardia, Abbott, Novartis, and Pfizer.
Dr Martin Maron, MD, Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, has received financial compensation for consulting for Cytokinetics and Imbria, and received research grants from Takeda and iRhythm.
Disclosure of educational planners:
Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.
Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
All relevant financial relationships have been mitigated.